JP2019522037A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522037A5 JP2019522037A5 JP2019504916A JP2019504916A JP2019522037A5 JP 2019522037 A5 JP2019522037 A5 JP 2019522037A5 JP 2019504916 A JP2019504916 A JP 2019504916A JP 2019504916 A JP2019504916 A JP 2019504916A JP 2019522037 A5 JP2019522037 A5 JP 2019522037A5
- Authority
- JP
- Japan
- Prior art keywords
- hours
- hour
- vivo
- cell
- adjusted according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078313A JP7208659B2 (ja) | 2016-07-29 | 2021-05-06 | インドリノン化合物の使用 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368707P | 2016-07-29 | 2016-07-29 | |
| US62/368,707 | 2016-07-29 | ||
| US201662417572P | 2016-11-04 | 2016-11-04 | |
| US62/417,572 | 2016-11-04 | ||
| US201662422504P | 2016-11-15 | 2016-11-15 | |
| US62/422,504 | 2016-11-15 | ||
| US201662426107P | 2016-11-23 | 2016-11-23 | |
| US62/426,107 | 2016-11-23 | ||
| US201762503238P | 2017-05-08 | 2017-05-08 | |
| US62/503,238 | 2017-05-08 | ||
| US201762534067P | 2017-07-18 | 2017-07-18 | |
| US62/534,067 | 2017-07-18 | ||
| PCT/US2017/043979 WO2018022771A1 (en) | 2016-07-29 | 2017-07-26 | Uses of indolinone compounds |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020204766A Division JP7182304B2 (ja) | 2016-07-29 | 2020-12-10 | インドリノン化合物の使用 |
| JP2021078313A Division JP7208659B2 (ja) | 2016-07-29 | 2021-05-06 | インドリノン化合物の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019522037A JP2019522037A (ja) | 2019-08-08 |
| JP2019522037A5 true JP2019522037A5 (enExample) | 2019-10-17 |
| JP6885629B2 JP6885629B2 (ja) | 2021-06-16 |
Family
ID=61011754
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504916A Active JP6885629B2 (ja) | 2016-07-29 | 2017-07-26 | インドリノン化合物の使用 |
| JP2020204766A Active JP7182304B2 (ja) | 2016-07-29 | 2020-12-10 | インドリノン化合物の使用 |
| JP2021078313A Active JP7208659B2 (ja) | 2016-07-29 | 2021-05-06 | インドリノン化合物の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020204766A Active JP7182304B2 (ja) | 2016-07-29 | 2020-12-10 | インドリノン化合物の使用 |
| JP2021078313A Active JP7208659B2 (ja) | 2016-07-29 | 2021-05-06 | インドリノン化合物の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10159660B2 (enExample) |
| EP (1) | EP3490553B1 (enExample) |
| JP (3) | JP6885629B2 (enExample) |
| KR (2) | KR20210095721A (enExample) |
| CN (2) | CN109789127B (enExample) |
| CA (1) | CA3029851A1 (enExample) |
| MX (1) | MX395539B (enExample) |
| PH (1) | PH12019500070A1 (enExample) |
| SG (1) | SG11201811661TA (enExample) |
| TW (2) | TWI780061B (enExample) |
| WO (1) | WO2018022771A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111777596A (zh) * | 2014-10-09 | 2020-10-16 | 英克特诺治疗公司 | 吲哚酮化合物及其用途 |
| WO2017172368A1 (en) | 2016-03-31 | 2017-10-05 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| CN109789127B (zh) * | 2016-07-29 | 2022-03-25 | 英克特诺治疗公司 | 吲哚啉酮化合物的用途 |
| CN110818611B (zh) * | 2018-08-13 | 2023-01-24 | 中国科学院上海药物研究所 | 一类吲哚酮类化合物、其制备方法、药物组合物和用途 |
| US20200171001A1 (en) * | 2018-11-30 | 2020-06-04 | Aptose Biosciences Inc. | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
| US20240139153A1 (en) * | 2020-09-17 | 2024-05-02 | Oklahoma Medical Research Foundation | Inhibition of Endothelial ETS Family Transcription Factors Promotes Flow-Dependent Ocular Vessel Regression |
| US20240299558A1 (en) * | 2021-06-18 | 2024-09-12 | University Of Maryland, Baltimore | Proteolysis targeting chimeras and polypharmacological agents targeting bcl-2, and methods of use thereof |
| CA3175913A1 (en) | 2021-07-16 | 2023-01-16 | Celator Pharmaceuticals, Inc. | Liposomal formulations of bcl inhibitors |
| WO2025137592A2 (en) * | 2023-12-21 | 2025-06-26 | Anuj Bellare | Diazirine monomers and polymer compositions derived therefrom |
| WO2025235561A1 (en) * | 2024-05-08 | 2025-11-13 | Enspire Group LLC | Venetoclax oral drugs and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3483704D1 (de) | 1983-07-22 | 1991-01-17 | Du Pont | Phenylchinolinsaeure und derivate als antitumormittel. |
| ATE285769T1 (de) | 1998-12-04 | 2005-01-15 | Neurosearch As | Verwendung von isatinderivaten als ionenkanalaktivierende mittel |
| UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| WO2001064681A2 (en) | 2000-02-28 | 2001-09-07 | Sugen, Inc. | 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
| AU2005323437B2 (en) | 2004-04-30 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a C5-modified pyrimidine |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| WO2006117414A1 (es) | 2005-04-29 | 2006-11-09 | Proyecto De Biomedicina Cima, S.L. | Modelo animal no humano de sarcoma |
| WO2008046083A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
| AU2007341977B2 (en) | 2006-12-29 | 2013-05-23 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| EP2154966B1 (en) | 2007-04-20 | 2013-08-21 | The Research Foundation Of State University Of New York | Benzimidazoles and pharmaceutical compositions thereof |
| US8377992B2 (en) | 2007-10-22 | 2013-02-19 | The Wistar Institute | TRBD-binding effectors and methods for using the same to modulate telomerase activity |
| EP3401684B1 (en) | 2008-10-10 | 2022-03-16 | Dana Farber Cancer Institute, Inc. | Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides |
| JP5675629B2 (ja) * | 2008-10-21 | 2015-02-25 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ペプチドエポキシケトンを用いた併用療法 |
| US8710068B2 (en) | 2009-01-19 | 2014-04-29 | The Trustees Of The University Of Pennsylvania | Method of treating cancer using a survivin inhibitor |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| WO2012078519A2 (en) | 2010-12-06 | 2012-06-14 | Numerate, Inc. | 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 |
| CN102516152B (zh) | 2011-12-12 | 2014-12-10 | 华东师范大学 | 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用 |
| US20130259927A1 (en) | 2012-04-02 | 2013-10-03 | Gradalis, Inc. | Ewing's Sarcoma Bifunctional shRNA Design |
| NZ700612A (en) * | 2012-04-12 | 2016-09-30 | Univ Georgetown | Methods and compositions for treating ewings sarcoma family of tumors |
| WO2014015153A2 (en) | 2012-07-20 | 2014-01-23 | Star Biotechnology, Llc | Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1 |
| CA2905418C (en) | 2013-03-13 | 2023-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| US20160287592A1 (en) * | 2013-04-08 | 2016-10-06 | Pharmacyclics Llc | Ibrutinib combination therapy |
| EA027139B1 (ru) * | 2013-04-26 | 2017-06-30 | Бейджин, Лтд. | Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны |
| KR101500363B1 (ko) * | 2013-07-01 | 2015-03-16 | 현대자동차 주식회사 | 하이브리드 자동차의 동력전달장치 |
| CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
| CN103435606A (zh) | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2与GSK3β双重抑制剂及用途 |
| US9511050B2 (en) | 2013-10-24 | 2016-12-06 | Georgetown University | Methods and compositions for treating cancer |
| WO2015061752A1 (en) * | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
| JP2016538310A (ja) * | 2013-11-27 | 2016-12-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法 |
| CN105793251B (zh) * | 2013-12-05 | 2018-10-12 | 豪夫迈·罗氏有限公司 | 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物 |
| EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| WO2015187848A1 (en) * | 2014-06-04 | 2015-12-10 | Sampath Deepa | Hdac inhibitor and btk inhibitor combinations |
| WO2016014859A1 (en) * | 2014-07-25 | 2016-01-28 | Pharmacyclics Llc | Bet inhibitor and bruton's tyrosine kinase inhibitor combinations |
| CN107427524A (zh) * | 2014-08-28 | 2017-12-01 | 翁科埃斯克斯有限公司 | 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法 |
| CN111777596A (zh) | 2014-10-09 | 2020-10-16 | 英克特诺治疗公司 | 吲哚酮化合物及其用途 |
| WO2017172368A1 (en) | 2016-03-31 | 2017-10-05 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| CN109789127B (zh) | 2016-07-29 | 2022-03-25 | 英克特诺治疗公司 | 吲哚啉酮化合物的用途 |
| US20190255127A1 (en) | 2018-02-21 | 2019-08-22 | Batu Biologics, Inc. | Augmentation of Oncolytic Viral Efficacy through Immunological Targeting Tumor Endothelial Cells |
-
2017
- 2017-07-26 CN CN201780059006.8A patent/CN109789127B/zh active Active
- 2017-07-26 SG SG11201811661TA patent/SG11201811661TA/en unknown
- 2017-07-26 KR KR1020217023307A patent/KR20210095721A/ko not_active Ceased
- 2017-07-26 US US15/660,566 patent/US10159660B2/en active Active
- 2017-07-26 KR KR1020197005697A patent/KR102282794B1/ko active Active
- 2017-07-26 CA CA3029851A patent/CA3029851A1/en active Pending
- 2017-07-26 EP EP17835216.7A patent/EP3490553B1/en active Active
- 2017-07-26 CN CN202210216619.0A patent/CN114569606B/zh active Active
- 2017-07-26 JP JP2019504916A patent/JP6885629B2/ja active Active
- 2017-07-26 WO PCT/US2017/043979 patent/WO2018022771A1/en not_active Ceased
- 2017-07-26 MX MX2019000867A patent/MX395539B/es unknown
- 2017-07-28 TW TW106125399A patent/TWI780061B/zh active
- 2017-07-28 TW TW111135922A patent/TWI857351B/zh active
-
2018
- 2018-08-27 US US16/114,076 patent/US10646470B2/en active Active
-
2019
- 2019-01-10 PH PH12019500070A patent/PH12019500070A1/en unknown
-
2020
- 2020-04-13 US US16/847,516 patent/US11285132B2/en active Active
- 2020-12-10 JP JP2020204766A patent/JP7182304B2/ja active Active
-
2021
- 2021-05-06 JP JP2021078313A patent/JP7208659B2/ja active Active
-
2022
- 2022-03-28 US US17/705,746 patent/US12161626B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Janiszewski et al. | Content and process priming: A review | |
| WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
| MX2024010140A (es) | Nuevos metodos. | |
| JP2015057451A5 (enExample) | ||
| WO2015165413A8 (zh) | 一种新型的稳定型抗体药物耦联物及其制备方法和用途 | |
| PH12018501903B1 (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| WO2015121348A3 (en) | Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor | |
| EP4545143A3 (en) | Early intervention methods to prevent or ameliorate toxicity | |
| EP3682875A3 (en) | Methods of treating pediatric metabolic syndrome | |
| MY189466A (en) | Methods of modulating drug plasma levels using erythrohydroxybupropion | |
| MX2016006318A (es) | 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso. | |
| TN2016000083A1 (en) | Methods and tools relating to the administration of contrast medium | |
| MX2020001342A (es) | Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas. | |
| JP2019532634A5 (enExample) | ||
| PH12017501304A1 (en) | Levodopa and carbidopa intestinal gel and method of use | |
| HK1255481A1 (zh) | 用於治疗hcv的方法 | |
| JP2017061488A5 (enExample) | ||
| EP4389218A3 (en) | Composition for treating joint disease and kit containing same | |
| NZ712584A (en) | Antitumor agent including irinotecan hydrochloride hydrate | |
| CO2020000529A2 (es) | Metodos para tratar hiperinsulinismo congenito | |
| JP2019518052A5 (enExample) | ||
| ME02839B (me) | Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt | |
| UA117105U (uk) | Спосіб застосування препарату xyla для анестезії плідників осетрових в процесі штучного відтворення | |
| HK1214511A1 (zh) | 盐酸兰地洛尔在快速性心律失常的长期治疗中的用途 | |
| HK1224578A1 (en) | Drug mixing and delivery system and method |